JCI table of contents: April 22, 2008(the CCND2 gene and the CCND1 gene. Furth...)

Date:4/22/2008

the CCND2 gene and the CCND1 gene. Further analysis revealed that the chemical inhibited the expression of both cyclin D1 and cyclin D2 in cells from individuals with multiple myeloma and myeloma cell lines, causing the cells to stop growing and to die. The chemical also prevented myeloma cell lines from growing when transplanted into mice. The authors have therefore suggested that these data provide a good rationale for further exploration of the ability of kinetin riboside and other drugs that target cyclin D1 and/or cyclin D2 to benefit individuals with cancers characterized by a reliance on either cyclin D1 or cyclin D2, such as many individuals with multiple myeloma.

TITLE: Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

AUTHOR CONTACT:
A. Keith Stewart
Mayo Clinic, Scottsdale, Arizona, USA.
Phone: (480) 301 4411; Fax: (480) 301 8387; E-mail: stewart.keith@mayo.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=34149

---

REPRODUCTIVE BIOLOGY: How is a regulator of sex hormone production regulated itself?

The production of the sex hormones testosterone, progesterone, and estrogen is controlled by two other hormones, which are known as luteinizing hormone (LH) and follicle stimulating hormone (FSH). Disturbances in the levels of either LH or FSH affect the production of sex hormones and can cause either premature or delayed puberty as well as infertility. New data, generated in mice by Jacques Baenziger and colleagues, at Washington University School of Medicine, St. Louis, have identified a new mechanism by which levels of LH in the blood are regulated.

Attached to LH are unique carbohydrate structures that end in a carbohydrate unit known as GalNAc-4-SO4. In the study, mice lacking the prot
'/>"/>

Contact: Karen Honey press_releases@the-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
2. Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
6. JCI online early table of contents: March 6, 2008
7. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
8. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
9. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
10. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
11. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net